Association of Interferon-Gamma Inducible Protein 10 Polymorphism with Treatment Response to Pegylated Interferon in HBeAg-Positive Chronic Hepatitis B
Free accessResearch articleFirst published online February, 2016
Association of Interferon-Gamma Inducible Protein 10 Polymorphism with Treatment Response to Pegylated Interferon in HBeAg-Positive Chronic Hepatitis B
Interferon-gamma inducible protein 10 (IP-10) plays an important role in the clinical outcome of chronic hepatitis B (CHB). This study aimed to investigate the association between single nucleotide polymorphisms (SNPs) G-201A of the IP-10 gene and treatment response to pegylated interferon (PEG-IFN) in patients with hepatitis B e antigen (HBeAg)-positive CHB.
Methods
We retrospectively analysed data of patients with HBeAg-positive CHB treated with PEG-IFN for 48 weeks. Virological response (VR) was defined as HBeAg clearance and HBV DNA <2,000 IU/ml at 24 weeks post-treatment. The SNPs G-201A, IFNL3 (rs12979860) and HLA-DPA1 (rs3077) were assessed.
Results
Among 107 patients, VR was achieved in 45 (42.1%) patients. Hepatitis B surface antigen (HBsAg) clearance and decline (<100 IU/ml) were observed in 10 (9.3%) and 22 (20.6%) patients, respectively. The distribution of GG, GA and AA genotypes of G-201A was 76.6%, 19.6% and 3.7%, respectively. Patients with GG genotype, compared to those with non-GG genotype, achieved higher VR rate (48.8% versus 19.2%; P=0.011), decreased HBsAg (25.6% versus 4.0%; P=0.019), and demonstrated a trend in HBsAg clearance (11.0% versus 4%; P=0.294). Patients with GG genotype had more rapid HBsAg decline and higher baseline serum IP-10 levels than those with non-GG genotype (432.2 ±339.0 versus 257.3 ±145.7 pg/ml; P=0.028). SNPs rs12979860 and rs3077 were not associated with VR. Logistic regression analysis suggested that SNP G-201A was an independent predictor of VR (odds ratio 3.81, 95% CI 1.31, 11.12; P=0.014).
Conclusions
Data from this study demonstrated for the first time that IP-10 polymorphism is independently associated with treatment response to PEG-IFN in patients with HBeAg-positive CHB.
References
1.
TrépoC., ChanH.L., LokA.Hepatitis B virus infection.Lancet2014; 384: 2053–2063.
2.
HoofnagleJ.H., DooE., LiangT.J.Management of hepatitis B: summary of a clinical research workshop.Hepatology2007; 45: 1056–1075.
3.
ScaglioneS.J., LokA.S.Effectiveness of hepatitis B treatment in clinical practice.Gastroenterology2012; 142: 1360–1368.
4.
StättermayerA.F., ScherzerT., BeinhardtS.Review article: genetic factors that modify the outcome of viral hepatitis.Aliment Pharmacol Ther2014; 39: 1059–1070.
5.
GeD., FellayJ., ThompsonA.J.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature2009; 461: 399–401.
6.
SuppiahV., MoldovanM., AhlenstielG.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.Nat Genet2009; 41: 1100–1104.
7.
TanakaY., NishidaN., SugiyamaM.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.Nat Genet2009; 41: 1105–1109.
8.
KamataniY., WattanapokayakitS., OchiH.A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.Nat Genet2009; 41: 591–595.
9.
BrouwerW.P., SonneveldM.J., TabakF.Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B.Aliment Pharmacol Ther2014; 40: 811–818.
10.
ChengL., SunX., TanS.Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients.Hepatol Res2014; 44: 1000–1007.
11.
NarumiS., TominagaY., TamaruM.Expression of IFN-inducible protein-10 in chronic hepatitis.J Immunol1997; 158: 5536–5544.
12.
DufourJ.H., DziejmanM., LiuM.T.IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking.J Immunol2002; 168: 3195–3204.
13.
AskariehG., AlsioA., PugnaleP.Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.Hepatology2010; 51: 1523–1530.
14.
DiagoM., CastellanoG., Garcia-SamaniegoJ.Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.Gut2006; 55: 374–379.
15.
LaggingM., AskariehG., NegroF.Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.PLoS ONE2011; 6: e17232.
16.
SonneveldM.J., ArendsP., BoonstraA.Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.J Hepatol2013; 58: 898–903.
17.
PapatheodoridisG., GoulisJ., ManolakopoulosS.Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.J Hepatol2014; 60: 62–68.
18.
WiegandS.B., JaroszewiczJ., PotthoffA.Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-gamma-induced protein 10 levels in HBV/HCV-coinfected patients.Clin Microbiol Infect2015; 21: 710.e1–710.e9.
19.
DengG., ZhouG., ZhangR.Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers.Gastroenterology2008; 134: 716–726.
20.
XuZ., LiuY., LiuL.Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population.PLoS ONE2013; 8: e72799.
21.
European Association For The Study Of The Liver.EASL clinical practice guidelines: management of chronic hepatitis B virus infection.J Hepatol2012; 57: 167–185.
22.
TangkijvanichP., Sa-NguanmooP., MahachaiV.A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma.Hepatol Int2010; 4: 577–584.
23.
PosuwanN., PayungpornS., TangkijvanichP.Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in Thai population.PLoS ONE2014; 9: e86007.
24.
AkkarathamrongsinS., ThongV.D., PayungpornS.IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.J Med Virol2014; 86: 1482–1490.
25.
WangY., ZhaoC., ZhangL.Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.Antiviral Res2014; 103: 51–59.
26.
CasteraL., PinzaniM., BoschJ.Non invasive evaluation of portal hypertension using transient elastography.J Hepatol2012; 56: 696–703.
27.
JaroszewiczJ., HoH., MarkovaA.Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues.Antivir Ther2011; 16: 915–924.
28.
MoucariR., KorevaarA., LadaO.High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.J Hepatol2009; 50: 1084–1092.
29.
ChanH.L., WongG.L., TseC.H.Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients.J Infect Dis2011; 204: 408–414.
30.
ChenY.C., JengW.J., ChuC.M.Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection.Clin Gastroenterol Hepatol2012; 10: 297–302.
31.
HondaM., SakaiA., YamashitaT.Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.Gastroenterology2010; 139: 499–509.
32.
CasrougeA., DecalfJ., AhloulayM.Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.J Clin Invest2011; 121: 308–317.
33.
ZhouY., WangS., MaJ.W.Hepatitis B virus protein X-induced expression of the CXC chemokine IP-10 is mediated through activation of NF-kappaB and increases migration of leukocytes.J Biol Chem2010; 285: 12159–12168.
34.
ChenS.H., WuH.L., KaoJ.H.Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors.PLoS ONE2012; 7: e36984.
35.
HouF.Q., WuX.J., WangY.Rapid downregulation of programmed death-1 and interferon-gamma-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B.J Viral Hepat2013; 20Suppl 1: 18–26.
36.
SonneveldM.J., WongV.W., WoltmanA.M.Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.Gastroenterology2012; 142: 513–520.
37.
WuH., ZhaoG., QianF.Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B.Liver Int2015; 35: 473–481.
38.
HolmesJ.A., NguyenT., RatnamD.IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha.J Gastroenterol Hepatol2013; 28: 861–866.
39.
ZhangQ., LapalusM., AsselahT.IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.J Viral Hepat2014; 21: 525–532.
40.
TsengT.C., YuM.L., LiuC.J.Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy.Antivir Ther2011; 16: 629–637.
